View an illustration about the life cycle of the malaria parasite.
MRTC is viewed by many as a model for research centers in developing countries, as its research is planned, directed, and executed by African scientists. It also provides a robust training program to help form the new generation of Malian scientists critical to the success and sustainability of the program. Current training at MRTC includes programs in biology, tropical medicine, medical entomology, and epidemiology.
The NIAID Laboratory of Malaria and Vector Research (LMVR) conducts studies at MRTC focused on two primary areas:
Researchers at MRTC have also collaborated with scientists at the NIAID Laboratory of Malaria Immunology and Vaccinology to develop sites for clinical studies of an LMIV-developed "blood stage" malaria vaccine. Researchers are testing the experimental vaccine to see if it reduces episodes of malaria parasitemia (parasites in the blood) in children exposed to the disease.
LMVR has recently established a research program at MRTC on leishmaniasis, a parasitic infection transmitted by the sand fly. In Mali, the disease is poorly documented, but preliminary studies at MRTC have shown that cutaneous leishmaniasis (the form of the disease that affects the skin) may be widespread—though usually undiagnosed. As a result, Mali could be a future trial site for leishmaniasis vaccines being developed in LMVR.
In addition to NIAID support, MRTC labs receive funding from several other international and U.S. agencies, organizations, and universities.
back to top
Last Updated April 06, 2008